| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kazia Therapeutics Limited | Paxalisib - (A071701) | Brain Metastases | Phase 2 | Data Released | Oral | Oncology |
| Kazia Therapeutics Limited | Paxalisib with Metformin | Glioblastoma | Phase 2 | Oral | Oncology | |
| Kazia Therapeutics Limited | Paxalisib (PNOC022) | Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMGs). | Phase 2 | Data Released | Oral | Oncology |
| Kazia Therapeutics Limited | Cantrixil | Ovarian cancer | Phase 2 | Intraperitoneal | Oncology | |
| Kazia Therapeutics Limited | Paxalisib (GDC-0084) with trastuzumab | Breast cancer brain metastases | Phase 2 | Oral with intravenous | Oncology | |
| Kazia Therapeutics Limited | Paxalisib - (A071701) | Brain Metastases | Phase 2 | Data Released | Oral | Oncology |
| Kazia Therapeutics Limited | Paxalisib with Metformin | Glioblastoma | Phase 2 | Oral | Oncology | |
| Kazia Therapeutics Limited | Paxalisib (PNOC022) | Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMGs). | Phase 2 | Data Released | Oral | Oncology |